Are embryonic stem cells really needed for regenerative medicine?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is estimated that as many as 1 in 3 individuals in the United States might benefit from regenerative medicine therapy. Most regenerative medicine therapies have been postulated to require the use of embryonic stem (ES) cells for optimal effect. Unfortunately, ES cell therapies are currently limited by ethical, political, regulatory, and most importantly biological hurdles. These limitations include the inherent allogenicity of this stem cell source and the accompanying threat of immune rejection. Even with use of the rapidly developing iPS technology, the issues of low efficiency of ES/iPS derivation and the threat of teratoma formation limit ES applications directly in patients. The time and cost of deriving and validating mature, differentiated tissues for clinical use further restricts its use to a small number of well-to-do patients with a limited number of afflictions. Thus, for the foreseeable future, the march of regenerative medicine to the clinic for widespread use will depend upon the development of non-ES cell therapies. Current sources of non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood. Each of these types of stem cells has already begun to be utilized to treat a variety of diseases.

Original languageEnglish (US)
Title of host publicationPluripotent Stem Cells
PublisherNova Science Publishers, Inc.
Pages185-190
Number of pages6
ISBN (Electronic)9781612092157
ISBN (Print)9781608767380
StatePublished - Jan 1 2010

Fingerprint

Regenerative Medicine
Embryonic Stem Cells
Stem cells
Stem Cells
Cell- and Tissue-Based Therapy
Teratoma
Fetal Blood
Tissue
Embryonic Development
Adipose Tissue
Bone Marrow
Technology
Costs and Cost Analysis
Bone
Blood
Therapeutics
Costs

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Harris, D. T. (2010). Are embryonic stem cells really needed for regenerative medicine? In Pluripotent Stem Cells (pp. 185-190). Nova Science Publishers, Inc..

Are embryonic stem cells really needed for regenerative medicine? / Harris, David T.

Pluripotent Stem Cells. Nova Science Publishers, Inc., 2010. p. 185-190.

Research output: Chapter in Book/Report/Conference proceedingChapter

Harris, DT 2010, Are embryonic stem cells really needed for regenerative medicine? in Pluripotent Stem Cells. Nova Science Publishers, Inc., pp. 185-190.
Harris DT. Are embryonic stem cells really needed for regenerative medicine? In Pluripotent Stem Cells. Nova Science Publishers, Inc. 2010. p. 185-190
Harris, David T. / Are embryonic stem cells really needed for regenerative medicine?. Pluripotent Stem Cells. Nova Science Publishers, Inc., 2010. pp. 185-190
@inbook{0597cc860088480baaa6dab62b375c04,
title = "Are embryonic stem cells really needed for regenerative medicine?",
abstract = "It is estimated that as many as 1 in 3 individuals in the United States might benefit from regenerative medicine therapy. Most regenerative medicine therapies have been postulated to require the use of embryonic stem (ES) cells for optimal effect. Unfortunately, ES cell therapies are currently limited by ethical, political, regulatory, and most importantly biological hurdles. These limitations include the inherent allogenicity of this stem cell source and the accompanying threat of immune rejection. Even with use of the rapidly developing iPS technology, the issues of low efficiency of ES/iPS derivation and the threat of teratoma formation limit ES applications directly in patients. The time and cost of deriving and validating mature, differentiated tissues for clinical use further restricts its use to a small number of well-to-do patients with a limited number of afflictions. Thus, for the foreseeable future, the march of regenerative medicine to the clinic for widespread use will depend upon the development of non-ES cell therapies. Current sources of non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood. Each of these types of stem cells has already begun to be utilized to treat a variety of diseases.",
author = "Harris, {David T.}",
year = "2010",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781608767380",
pages = "185--190",
booktitle = "Pluripotent Stem Cells",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Are embryonic stem cells really needed for regenerative medicine?

AU - Harris, David T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - It is estimated that as many as 1 in 3 individuals in the United States might benefit from regenerative medicine therapy. Most regenerative medicine therapies have been postulated to require the use of embryonic stem (ES) cells for optimal effect. Unfortunately, ES cell therapies are currently limited by ethical, political, regulatory, and most importantly biological hurdles. These limitations include the inherent allogenicity of this stem cell source and the accompanying threat of immune rejection. Even with use of the rapidly developing iPS technology, the issues of low efficiency of ES/iPS derivation and the threat of teratoma formation limit ES applications directly in patients. The time and cost of deriving and validating mature, differentiated tissues for clinical use further restricts its use to a small number of well-to-do patients with a limited number of afflictions. Thus, for the foreseeable future, the march of regenerative medicine to the clinic for widespread use will depend upon the development of non-ES cell therapies. Current sources of non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood. Each of these types of stem cells has already begun to be utilized to treat a variety of diseases.

AB - It is estimated that as many as 1 in 3 individuals in the United States might benefit from regenerative medicine therapy. Most regenerative medicine therapies have been postulated to require the use of embryonic stem (ES) cells for optimal effect. Unfortunately, ES cell therapies are currently limited by ethical, political, regulatory, and most importantly biological hurdles. These limitations include the inherent allogenicity of this stem cell source and the accompanying threat of immune rejection. Even with use of the rapidly developing iPS technology, the issues of low efficiency of ES/iPS derivation and the threat of teratoma formation limit ES applications directly in patients. The time and cost of deriving and validating mature, differentiated tissues for clinical use further restricts its use to a small number of well-to-do patients with a limited number of afflictions. Thus, for the foreseeable future, the march of regenerative medicine to the clinic for widespread use will depend upon the development of non-ES cell therapies. Current sources of non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood. Each of these types of stem cells has already begun to be utilized to treat a variety of diseases.

UR - http://www.scopus.com/inward/record.url?scp=85060201866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060201866&partnerID=8YFLogxK

M3 - Chapter

SN - 9781608767380

SP - 185

EP - 190

BT - Pluripotent Stem Cells

PB - Nova Science Publishers, Inc.

ER -